What if treating type 1 diabetes eventually required just one injection — not daily, not weekly, but once? That's the idea behind a new gene therapy now entering clinical trials.

What Is KRIYA-839?

KRIYA-839 is an experimental gene therapy being tested in a clinical study called PROGRESS. Participants with type 1 diabetes receive a single intramuscular injection — into the quadriceps — that is designed to reprogram muscle cells to produce insulin.

The body has an enormous amount of muscle tissue. If even a small fraction of those cells could be coaxed into making insulin, the hope is that blood sugar could be regulated more naturally — reducing or even eliminating the need for external insulin.

Why Muscle? Why Not the Pancreas?

One of the challenges with T1D is that the immune system has declared war on the pancreas. Transplanting new beta cells back into the pancreas — or into nearby tissue — often means putting them back in the line of fire. Using muscle cells instead is a clever workaround: these cells don't carry the same autoimmune target on their back.

Early Days, Real Questions

PROGRESS is an early-stage trial, meaning it is primarily testing safety — is the treatment safe for humans? — before measuring how well it works. The road from here to an approved therapy for children is long.

But for parents watching the horizon, it's worth knowing that gene therapy for T1D is no longer a thought experiment. It is in human trials now.

What This Means for Your Family Today

Nothing changes in your child's management today because of this trial. But as a community of T1D families, it matters to follow these developments. The more awareness, interest, and research support there is for T1D, the faster progress moves.

Keywords: gene therapy type 1 diabetes, KRIYA-839, PROGRESS trial T1D, type 1 diabetes cure research, T1D gene therapy 2026